Delving into the Latest Updates on Sodium Picosulfate Hydrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Picosulfate, Picosulphate, Sodium Picosulfate

+ [15]

Target-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Contrast agentsIntestinal preparationConstipation

Inactive Indication

Constipation - functionalDiffuse Large B-Cell LymphomaGastrointestinal Diseases+ [1]

Originator Organization

Sanofi

Active Organization

Viatris Healthcare GmbHTeijin Pharma Ltd.

Sanofi

+ [1]

Inactive Organization

Ferring BV

Chongqing Lummy Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

JP (27 Aug 1979),

Constipation

Regulation-

Login to view timeline

Structure

Molecular FormulaC18H17NNa2O9S2

InChIKeyPUKNPYFKPBSERR-UHFFFAOYSA-N

CAS Registry1307301-38-7

View All Structures (2)

AbstractAimTo evaluate whether the use of a laxative with reduced patient burden in oral antibiotics and mechanical bowel preparation (OAMBP) could prevent surgical site infection (SSI) in left‐sided colon and rectal cancers.MethodsThis multicenter, non‐blinded, randomized, non‐inferiority trial included patients who underwent elective colorectal surgery for colorectal cancer in a university and community hospital in Japan from April 1, 2021 to March 31, 2023. We compared conventional OAMBP (polyethylene glycol, metronidazole, and kanamycin) (cOAMBP group) with modified OAMBP (sodium picosulfate hydrate, metronidazole, and kanamycin) (mOAMBP group). The primary outcome was overall incidence of SSI. Secondary outcomes were postoperative complications, degree of patient burden, and intraoperative bowel dilatation.ResultsAmong 119 patients, 112 were randomly assigned to the two groups, with 56 patients in each group. SSI occurred in three (5.4%) and five patients (8.3%) in the mOAMBP and cOAMBP groups, respectively (90% confidence interval [CI]: −12.8–5.3), with a 15% margin of non‐inferiority. Anastomotic leakage occurred in no patient in the mOAMBP group and three patients (5.4%) in the cOAMBP group (p = 0.24). The cOAMBP group reported significantly more pain than the mOAMBP group (50 [90.9%] vs. 7 [12.5%] participants). The mOAMBP group showed significantly lesser bowel dilatation than the cOAMBP group (1 [1.8%] vs. 21 [37.5%] participants).ConclusionmOAMBP is safe and less burdensome, can reduce intraoperative bowel dilatation, and is non‐inferior compared with cOAMBP in preventing SSI. Therefore, mOAMBP may be more suitable for sigmoid colon and rectal cancer.Trial RegistrationUMIN000043162 (http://www.umin.ac.jp/ctr/). Registered on January 28, 2021.

01 Nov 2024·Digestive and Liver Disease

Superior bowel preparation quality for colonoscopy with 1L-PEG compared to 2L-PEG and picosulphate: Data from a large real-world retrospective outpatient cohort

Article

Author: Pozzi, Lodovica ; Mauro, Aurelio ; Mazza, Stefano ; Maimaris, Stiliano ; Di Sabatino, Antonio ; Agazzi, Simona ; Fazzino, Erica ; Rovedatti, Laura ; Lenti, Marco Vincenzo ; Schiepatti, Annalisa ; Anderloni, Andrea ; Bardone, Marco ; Biagi, Federico ; Alimenti, Eleonora ; Strada, Elena ; Scalvini, Davide ; Lusetti, Francesca

BACKGROUNDSeveral randomized clinical trials comparing different bowel preparations (BP) have shown similar efficacy; however, there is a lack of real-world studies on this topic.AIMSThis study aims to identify the most effective BP regimen in a real-world setting and any predictors of inadequate BP.METHODSA retrospective single-center study was conducted over 14 months at an academic hospital including outpatient colonoscopies in which adult patients did not teach on how to perform BP before colonoscopy. Colonoscopies with 1L-PEG, 2L-PEG and picosulphate mixtures were considered. A multivariable analysis for factors associated to poor BP was fitted.RESULTSOverall, 1779 patients (51 %F, 60±14) years were included. The 1L-PEG regimen provided a higher rate of BP adequacy at multivariate analysis (adjusted OR 2.30, 95 %CI 1.67-3.16,p < 0.001) and was associated with higher median Boston Bowel Preparation Scale score (p < 0.001), higher rate of right-colon cleansing (p < 0.001) and exam completion (p = 0.04). Furthermore, we identified male sex, history of constipation, active smoking, previous pelvic surgery, concomitant psychiatric/neurological or chronic kidney diseases as predictors of inadequate BP.CONCLUSIONSThis is the largest real-world study comparing 1L-PEG to other BP regimens. Our results suggest 1L-PEG provides better BP in a non-controlled setting, improving clinical practice quality and minimizing the need for repeated colonoscopies and saving healthcare resources.

1

News (Medical) associated with Sodium Picosulfate Hydrate

25 May 2023

·www.drugs.com

Guidelines Developed for Treating Chronic Idiopathic Constipation

THURSDAY, May 25, 2023 -- In a clinical practice guideline issued by the American Gastroenterological Association and the American College of Gastroenterology, and published online May 19 in the American Journal of Gastroenterology and Gastroenterology , recommendations are presented for the pharmacologic treatment of chronic idiopathic constipation (CIC) in adults. Lin Chang, M.D., from the David Geffen School of Medicine at the University of California in Los Angeles, and colleagues conducted systematic reviews relating to use of fiber, osmotic laxatives, stimulant laxatives, secretagogues, and serotonin type 4 agonists to provide evidence-based practice recommendations for treatment of CIC in adults. The multidisciplinary guideline panel agreed on 10 recommendations for pharmacological management of CIC. These included strong recommendations for use of polyethylene glycol, sodium picosulfate, linaclotide, plecanatide, and prucalopride, based on moderate certainty of evidence. Conditional recommendations, based on low or very low certainty of evidence, were made for fiber supplementation, lactulose, senna, magnesium oxide, and lubiprostone. "The guidelines are meant to provide a framework for approaching the management of CIC," the authors write. "Clinical providers should engage in shared decision-making based on patient preferences as well as medication cost and availability." Several authors disclosed ties to the pharmaceutical, medical device, and other industries. Several authors hold patents, including for a rectal expulsion device. Abstract/Full Text Posted May 2023

100 Deals associated with Sodium Picosulfate Hydrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01612	Sodium Picosulfate Hydrate	A06AB08	DB09268

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Contrast agents	JP	Viatris Healthcare GmbH	01 Jul 1992
Intestinal preparation	JP	Teijin Pharma Ltd.	27 Mar 1992
Constipation	JP	Teijin Pharma Ltd.	27 Aug 1979
Constipation	JP	Sanofi	27 Aug 1979

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastrointestinal Diseases	Preclinical	FR	Ferring BV	01 Nov 2014
Gastrointestinal Diseases	Preclinical	DE	Ferring BV	01 Nov 2014
Gastrointestinal Diseases	Preclinical	NL	Ferring BV	01 Nov 2014
Diffuse Large B-Cell Lymphoma	Preclinical	JP	Ferring BV	01 Sep 2014
Constipation - functional	Preclinical	CN	Chongqing Lummy Pharmaceutical Co., Ltd.	16 Sep 2011
Pharmaceutical aids	Preclinical	US	Ferring BV	01 May 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MORA: NOCT: DAYB (UEGW)	Phase 3	-	1,985	NER1006 (N2D)	yjksyidtcc(tfjbaecoym) = rpknfzomfy qeoioutuzo (bezjkccnvl ) View more	Positive	01 Oct 2019
				2L PEG+ascorbate (2LPEG)	yjksyidtcc(tfjbaecoym) = ddumrhhsdk qeoioutuzo (bezjkccnvl ) View more
UEGW	Not Applicable	-	-	Picosalax	rinpyprkic(efwjlgqkcp) = oqkmlhuzbe vrbsvedkux (tzipxsokan )	-	01 Oct 2014
				Polyethylene Glycol (PEG)	rinpyprkic(efwjlgqkcp) = dtaztjovxb vrbsvedkux (tzipxsokan )